Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 11, 2019 Filed Feb 13, 2019 21:40 UTC |
Sachdev AmitEVP, CRO
|
SaleCommon Stock | 5,406 | $180.85 | $977,675.10 |
DisclosureSEC source: 0001209191-19-009667 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,265 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $180.85 (range $180.65 to $181.63). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:40 UTC |
Sachdev AmitEVP, CRO
|
SaleCommon Stock | 19,021 | $180.17 | $3,427,013.57 |
DisclosureSEC source: 0001209191-19-009667 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,671 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $180.17 (range $179.64 to $180.64). Read SEC document |
| February 11, 2019 Filed Feb 13, 2019 21:40 UTC |
Sachdev AmitEVP, CRO
|
SaleCommon Stock | 10,568 | $179.44 | $1,896,321.92 |
DisclosureSEC source: 0001209191-19-009667 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,692 F1 · kind: Transaction made pursuant to Mr. Sachdev's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $179.44 (range $178.61 to $179.61). F3 · price: Mr. Sachdev undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:04 UTC |
Silva Paul MSVP & Interim CFO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,289 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-008045 · doc4.xml · derivative · entry 4 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,157 Underlying: Common Stock · 1,289 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:04 UTC |
Silva Paul MSVP & Interim CFO
|
SaleCommon Stock | 1,289 | $193.00 | $248,777.00 |
DisclosureSEC source: 0001209191-19-008045 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,649 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 06, 2019 Filed Feb 7, 2019 21:04 UTC |
Silva Paul MSVP & Interim CFO
|
Exercise / conversionCommon Stock | 1,289 | $91.05 | $117,363.45 |
DisclosureSEC source: 0001209191-19-008045 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,938 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:33 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantStock Option (Right to Buy) · Derivative | 25,026 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008538 · doc4.xml · derivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,026 Underlying: Common Stock · 25,026 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:33 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantCommon Stock | 9,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008538 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,937 F3 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:33 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008538 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,138 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/6/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:33 UTC |
Arbuckle Stuart AEVP\Chief Commercial Officer
|
GrantCommon Stock | 17,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008538 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,700 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019 and the shares will vest on 2/10/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:37 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantStock Option (Right to Buy) · Derivative | 20,855 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008546 · doc4.xml · derivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,855 Underlying: Common Stock · 20,855 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:37 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 8,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008546 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,133 F3 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:37 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008546 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,967 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/6/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 2/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:37 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
GrantCommon Stock | 14,416 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008546 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,529 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 2/6/2019 and the shares will vest on 2/10/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:39 UTC |
Kewalramani ReshmaEVP and CMO
|
GrantStock Option (Right to Buy) · Derivative | 25,026 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008550 · doc4.xml · derivative · entry 3 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,026 Underlying: Common Stock · 25,206 shares Expires 2029-02-05 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:39 UTC |
Kewalramani ReshmaEVP and CMO
|
GrantCommon Stock | 9,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008550 · doc4.xml · nonDerivative · entry 2 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,224 F2 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:39 UTC |
Kewalramani ReshmaEVP and CMO
|
GrantCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008550 · doc4.xml · nonDerivative · entry 1 Kewalramani Reshma · CIK 0001735944 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,425 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/6/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:43 UTC |
Parini MichaelEVP, CL&AO
|
GrantStock Option (Right to Buy) · Derivative | 20,855 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008561 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,855 Underlying: Common Stock · 20,855 shares Expires 2029-02-05 F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:43 UTC |
Parini MichaelEVP, CL&AO
|
GrantCommon Stock | 8,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008561 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,763 F2 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:43 UTC |
Parini MichaelEVP, CL&AO
|
GrantCommon Stock | 8,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008561 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,597 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/6/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantStock Option (Right to Buy) · Derivative | 72,647 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · derivative · entry 5 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,647 Underlying: Common Stock · 72,647 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 28,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 238,623 F3 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 31,498 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,179 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:48 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 53,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008582 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,681 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019 and the shares will vest on 2/10/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC |
Silva Paul MSVP & Interim CFO
|
GrantStock Option (Right to Buy) · Derivative | 7,449 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · derivative · entry 5 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,449 Underlying: Common Stock · 7,449 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC |
Silva Paul MSVP & Interim CFO
|
GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · nonDerivative · entry 3 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,786 F3 · shares: Restricted stock unit award that vests on 2/28/2021. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC |
Silva Paul MSVP & Interim CFO
|
GrantCommon Stock | 2,917 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · nonDerivative · entry 2 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,786 F2 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:50 UTC |
Silva Paul MSVP & Interim CFO
|
GrantCommon Stock | 4,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008588 · doc4.xml · nonDerivative · entry 1 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,869 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC |
Sachdev AmitEVP, CRO
|
GrantStock Option (Right to Buy) · Derivative | 25,026 | $0.00 Strike: $187.53 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · derivative · entry 6 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,026 Underlying: Common Stock · 25,026 shares Expires 2029-02-05 F4 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC |
Sachdev AmitEVP, CRO
|
GrantCommon Stock | 9,799 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · nonDerivative · entry 3 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,260 F3 · shares: Restricted stock unit award that vests in installments beginning on 2/24/2020. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC |
Sachdev AmitEVP, CRO
|
GrantCommon Stock | 10,126 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · nonDerivative · entry 2 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,461 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/3/2018 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019. The earned performance shares will vest in installments beginning on 2/17/2019. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 21:51 UTC |
Sachdev AmitEVP, CRO
|
GrantCommon Stock | 17,298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-008592 · doc4.xml · nonDerivative · entry 1 Sachdev Amit · CIK 0001406338 · EVP, CRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,335 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 2/2/2016 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/6/2019 and the shares will vest on 2/10/2019. Read SEC document |
| February 05, 2019 Filed Feb 7, 2020 21:16 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 31,462 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007495 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,818 F3 · shares: Restricted stock unit award that will vest pursuant to his employment agreement upon Dr. Leiden's transition from CEO. Read SEC document |
| February 05, 2019 Filed Feb 7, 2020 21:16 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 28,444 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007495 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 185,356 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest in installments beginning on 02/24/2020. Read SEC document |
| February 05, 2019 Filed Feb 7, 2020 21:16 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
GrantCommon Stock | 50,566 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-007495 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,912 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:45 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-007758 · doc4.xml · derivative · entry 3 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,639 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:45 UTC |
Parini MichaelEVP, CL&AO
|
SaleCommon Stock | 2,330 | $189.19 | $440,812.70 |
DisclosureSEC source: 0001209191-19-007758 · doc4.xml · nonDerivative · entry 2 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,159 F1 · kind: Transaction made pursuant to Mr. Parini's company-approved trading plan under Rule 10b5-1. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:45 UTC |
Parini MichaelEVP, CL&AO
|
Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-19-007758 · doc4.xml · nonDerivative · entry 1 Parini Michael · CIK 0001661567 · EVP, CL&AO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,489 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:46 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,330 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-007761 · doc4.xml · derivative · entry 6 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,639 Underlying: Common Stock · 2,330 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:46 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 1,796 | $0.00 Strike: $91.05 | $0.00 |
DisclosureSEC source: 0001209191-19-007761 · doc4.xml · derivative · entry 5 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,184 Underlying: Common Stock · 1,796 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/02/2016. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:46 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 2,330 | $189.19 | $440,812.70 |
DisclosureSEC source: 0001209191-19-007761 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,113 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:46 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 2,330 | $86.52 | $201,591.60 |
DisclosureSEC source: 0001209191-19-007761 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,443 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:46 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 1,796 | $189.19 | $339,785.24 |
DisclosureSEC source: 0001209191-19-007761 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,113 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:46 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Exercise / conversionCommon Stock | 1,796 | $91.05 | $163,525.80 |
DisclosureSEC source: 0001209191-19-007761 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,909 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:47 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 900 | $187.91 | $169,119.00 |
DisclosureSEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 4 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 124,865 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $187.91 (range $187.51 to $188.25). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:47 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 12,951 | $186.70 | $2,417,951.70 |
DisclosureSEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 3 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,765 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $186.70 (range $186.39 to $187.29). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:47 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 17,099 | $186.10 | $3,182,123.90 |
DisclosureSEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 2 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,716 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $186.10 (range $185.55 to $186.38). Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:47 UTC |
LEIDEN JEFFREY MDirector · CEO & President
|
SaleCommon Stock | 1,300 | $184.99 | $240,487.00 |
DisclosureSEC source: 0001209191-19-007764 · doc4.xml · nonDerivative · entry 1 LEIDEN JEFFREY M · CIK 0001242825 · Director · CEO & President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 155,815 F1 · kind: Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $184.99 (range $184.49 to $185.38). F3 · price: Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC |
Silva Paul MSVP & Interim CFO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 809 | $0.00 Strike: $86.52 | $0.00 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · derivative · entry 7 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,472 Underlying: Common Stock · 809 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document |
| February 04, 2019 Filed Feb 6, 2019 21:49 UTC |
Silva Paul MSVP & Interim CFO
|
SaleCommon Stock | 120 | $188.33 | $22,599.60 |
DisclosureSEC source: 0001209191-19-007770 · doc4.xml · nonDerivative · entry 6 Silva Paul M · CIK 0001446372 · SVP & Interim CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,649 F1 · kind: Transaction made pursuant to Mr. Silva's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Silva undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $188.33 (range $188.25 to $188.35). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.